Ophthalmology

This study examined patient-reported survey data linked with Medicare claims to describe the burden of these vision-threatening retinal diseases among Medicare beneficiaries.

To evaluate whether infliximab, a modern off-label biologic, is cost-effective for treating posterior uveitis and panuveitis compared to current standards of care, methotrexate and prednisone.

To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan.